STAT July 7, 2022
America’s economically disadvantaged patients can point in two directions when talking about what is wrong with the 340B Drug Pricing Program, which is designed to help hospitals caring for underserved communities — and the patients they treat — keep necessary medicines reasonably priced: large supposedly “nonprofit” hospitals and for-profit pharmacy benefit managers that serve as 340B contract pharmacies, which together divert billions of dollars in savings that should be helping patients in need.
Begun in 1992, 340B is a federal program that requires drug manufacturers to provide significant discounts to eligible health care organizations that are supposed to treat high numbers of uninsured and low-income patients. This program is critically important to hemophilia, AIDS, and other community clinics known as...